• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/7/24 8:06:20 AM ET
    $CLLS
    $CNTX
    $COCH
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLLS alert in real time by email

    Gainers

    • FibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday.
    • Envoy Medical (NASDAQ:COCH) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million.
    • iSpecimen (NASDAQ:ISPC) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million.
    • GT Biopharma (NASDAQ:GTBP) shares rose 19.25% to $3.84. The market value of their outstanding shares is at $5.3 million.
    • Esperion Therapeutics (NASDAQ:ESPR) stock increased by 18.39% to $2.51. The company's market cap stands at $475.3 million. As per the news, the Q1 earnings report came out today.

    Losers

    • Helius Medical Tech (NASDAQ:HSDT) shares decreased by 16.5% to $2.02 during Tuesday's pre-market session. The company's market cap stands at $1.7 million.
    • Cellectis (NASDAQ:CLLS) shares declined by 11.05% to $2.98. The company's market cap stands at $214.4 million.
    • Eledon Pharma (NASDAQ:ELDN) shares fell 9.43% to $2.21. The market value of their outstanding shares is at $54.8 million.
    • Fresenius Medical Care (NYSE:FMS) stock fell 8.03% to $19.7. The company's market cap stands at $11.5 billion.
    • Madrigal Pharmaceuticals (NASDAQ:MDGL) shares declined by 7.42% to $218.1. The market value of their outstanding shares is at $4.6 billion. The company's, Q1 earnings came out today.
    • Context Therapeutics (NASDAQ:CNTX) shares declined by 7.31% to $1.65. The company's market cap stands at $26.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLLS
    $CNTX
    $COCH
    $ELDN

    CompanyDatePrice TargetRatingAnalyst
    Cellectis S.A.
    $CLLS
    2/17/2026$7.00Buy
    Jefferies
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Fresenius Medical Care AG
    $FMS
    1/20/2026Buy → Neutral
    Goldman
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/5/2025Neutral → Overweight
    Cantor Fitzgerald
    Madrigal Pharmaceuticals Inc.
    $MDGL
    11/3/2025$445.00Underperform → Neutral
    BofA Securities
    Fresenius Medical Care AG
    $FMS
    10/15/2025Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 7:18:32 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:49:18 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)

    4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

    3/6/26 6:34:05 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    SEC Filings

    View All

    SEC Form 10-K filed by Esperion Therapeutics Inc.

    10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 4:55:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 7:17:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

    144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    3/6/26 6:28:13 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Cellectis with a new price target

    Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00

    2/17/26 7:48:16 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Madrigal Pharmaceuticals with a new price target

    Barclays initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $964.00

    1/28/26 7:18:07 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fresenius Medical downgraded by Goldman

    Goldman downgraded Fresenius Medical from Buy to Neutral

    1/20/26 9:08:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CLLS
    $CNTX
    $COCH
    $ELDN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

    IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). "Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcin

    3/10/26 7:00:00 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

    Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune ModulationZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (NASDAQ:NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical-stage immunology company with a focus on transplant medicine. The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-

    3/9/26 7:00:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Leadership Updates

    Live Leadership Updates

    View All

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $CNTX
    $COCH
    $ELDN
    Financials

    Live finance-specific insights

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

    SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

    3/9/26 7:00:00 AM ET
    $FGEN
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance